Physician profile
Paul Albert
NPI 1932201316
$3,553.27
in general payments reported to CMS, 2019-2025
21 companies · $351 in 2025
The $351 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,114 · 2022: $745 · 2023: $898 · 2024: $445 · 2025: $351.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,694.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,694.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $797.05 | 2021-2023 | Xarelto |
| Pfizer INC. | $549.82 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $365.47 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $289.75 | 2021-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals Lp | $220.05 | 2021-2025 | Farxiga, Brilinta |
| Boston Scientific Corporation | $185.13 | 2024-2025 | Watchman Flx |
| Abbott Laboratories | $154.88 | 2021-2023 | Cardiomems |
| Medtronic, INC. | $144.91 | 2023 | Azure Xt Dr Mri Surescan |
| Merck Sharp & Dohme LLC | $141.25 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $130.13 | 2021-2025 | Lifevest |
| Novo Nordisk INC | $110.84 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.50 | 2021-2023 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $96.85 | 2021-2025 | |
| Actelion Pharmaceuticals US, INC. | $69.95 | 2021-2022 | |
| Amgen INC. | $62.59 | 2021-2023 | Repatha |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $34.30 | 2023 | |
| Kiniksa Pharmaceuticals, Ltd. | $30.10 | 2023 | Arcalyst |
| Philips North America LLC | $25.30 | 2024 | (Cm9) Amb Mon & Diag Und |
| Takeda Pharmaceuticals U.S.A., INC. | $16.27 | 2021 | |
| Amarin Pharma, INC. | $15.37 | 2021 | |
| Lilly USA, LLC | $11.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Albert listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.